The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance-Reference-Cited by-同舟云学术

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance

Published:2016-08-05 Issue:35 Volume:7 Page:57197-57212
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Alidzanovic Lejla¹,Starlinger Patrick¹,Schauer Dominic¹,Maier Thomas¹,Feldman Alexandra¹,Buchberger Elisabeth¹,Stift Judith²,Koeck Ulrike³,Pop Lorand¹,Gruenberger Birgit⁴,Gruenberger Thomas¹⁵,Brostjan Christine¹

Affiliation:

1. Department of Surgery, Medical University of Vienna, General Hospital, 1090 Vienna, Austria

2. Department of Pathology, Medical University of Vienna, General Hospital, 1090 Vienna, Austria

3. Department of Neuroimmunology, Medical University of Vienna, Center for Brain Research, 1090 Vienna, Austria

4. Department of Internal Medicine, Hospital of The Merciful Brothers, 1020 Vienna, Austria

5. Current address: Department of Surgery I, Rudolf Foundation Clinic, 1030 Vienna, Austria

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early 2-Factor Transcription Factors Associated with Progression and Recurrence in Bevacizumab-Responsive Subtypes of Glioblastoma;Cancers;2024-07-14

2. Endogenous IL-27 during toxoplasmosis limits early monocyte responses and their inflammatory activation by pathological T cells;mBio;2024-03-13

3. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G;Targeted Oncology;2024-03

4. Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design;Neuro-Oncology Advances;2024-01-01

5. Unleashing the power of antibodies: Engineering for tomorrow’s therapy;Advances in Protein Chemistry and Structural Biology;2024